IFP Advisors’s Esperion Therapeutics ESPR Stock Holding History

IFP Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9	Sell	3 -3	-50%	-$8	﹤0.01%	5095
2026 Q1	$16	Hold	6	–	–	﹤0.01%	4940
2025 Q4	$22	Buy	6 +3	+100%	+$10	﹤0.01%	4798
2025 Q3	$8	Buy	+3	New	+$6	﹤0.01%	4791
2023 Q3	–	Sell	-44	Closed	-$61	–	3379
2023 Q2	$61	Hold	44	–	–	﹤0.01%	3380
2023 Q1	$1.67K	Buy	+44	New	+$227	﹤0.01%	2952
2020 Q1	–	Sell	-9	Closed	-$475	–	2824
2019 Q4	$1K	Hold	9	–	–	﹤0.01%	2652
2019 Q3	$0	Buy	+9	New	+$357	﹤0.01%	3086
2019 Q1	–	Sell	-9	Closed	–	–	2658
2018 Q4	$0	Buy	+9	New	+$434	﹤0.01%	3625
2017 Q2	–	Sell	-800	Closed	-$28K	–	4113
2017 Q1	$28K	Buy	800 +794	+13,233%	+$18.2K	﹤0.01%	2280
2016 Q4	$0	Hold	6	–	–	﹤0.01%	4016
2016 Q3	$0	Hold	6	–	–	﹤0.01%	3935
2016 Q2	$0	Buy	+6	New	+$99	﹤0.01%	3889

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

IFP Advisors's ESPR Position: Q2 2026 in Review

IFP Advisors reduced its Esperion Therapeutics (ESPR) stake by 50% in Q2 2026, selling an estimated $8 and leaving 3 shares worth $9. The position accounts for ﹤0.01% of the portfolio, ranked #5095.

IFP Advisors first reported a position in ESPR in Q2 2016 and has held it in 13 quarters since. The position peaked at $28K in Q1 2017. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

IFP Advisors held 3 shares of Esperion Therapeutics worth $9 as of Q2 2026.
IFP Advisors sold 3 Esperion Therapeutics shares in Q2 2026, an estimated $8.
Esperion Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #5095 holding.
IFP Advisors first reported a position in Esperion Therapeutics in Q2 2016 and has held it in 13 quarters since.
IFP Advisors's Esperion Therapeutics position peaked at $28K in Q1 2017.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.